Sebastian Gensior

Welcome back to Fun with Funds, where we break down intriguing financial vehicles in plain English. Today’s guest is the SPDR S&P Biotech ETF (XBI), a fund that acts like a backstage pass to the high-stakes world of biotechnology. This isn’t your run-of-the-mill ETF; the XBI

SPACs and Biotech: A Cautionary Tale In recent years, Special Purpose Acquisition Companies (SPACs) emerged as a popular alternative to traditional IPOs, offering a faster route to public markets. This trend was particularly notable in the biotech sector, where companies are often in constant need of capital to fund research

Davos in January. The snow-dusted mountains, the high-altitude air of importance, and the collective hum of thousands of people all trying to solve the world’s problems—or at least network with people who say they are. It’s the annual meeting of the World Economic Forum, where being “in

It is a truth universally acknowledged that a brilliant researcher in possession of a good idea is often too timid to take it beyond the lab bench. This is particularly true in Europe, where scientific breakthroughs languish in the warm embrace of public funding, wrapped snugly in the comfort of

A few years ago, if someone had told me you could walk into a bank, lay a patent on the table, and walk out with a loan, I would have laughed. Yet, in South Korea, this isn’t just an idea—it’s reality. They’ve built a system that

Medicocristan is a place where mediocrity reigns supreme. Its streets are orderly, its people are risk-averse, and its leaders champion safety over boldness. It’s a world where the "tried and true" always beats the "unproven and risky," and where every decision must pass the scrutiny

It’s a tale as old as the severance check. A veteran employee—newly liberated from the corporate mothership—decides that instead of searching for another job, they will take their decades of experience and launch a consulting career. Why not? They know the industry inside out, have a bulging

The MBA, that once-illustrious badge of business acumen, has long held a peculiar sway over boardrooms and balance sheets. It promises to transform mere mortals into "masters of the universe," armed with spreadsheets, frameworks, and an uncanny ability to speak in acronyms. Yet in industries like biotech and

Drug development requires vast investments of capital and time. Even after extensive research and clinical testing, unforeseen safety problems or unexpectedly high efficacy in niche populations can dramatically alter a drug’s commercial and therapeutic trajectory. Traditional statistical methods typically focus on the mean or median response, but it is

Conformity is often the lubricant of social interaction. It smooths edges, creates predictability, and allows societies and organizations to function with a semblance of order. Yet, in fields like venture capital, biotech, and pharma, conformity often does little more than uphold mediocrity. Breakthroughs in these industries come not from towing